Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.78 |
| ▸ | GAK | O14976 | 3/20 | 0.75 |
| ▸ | ABL1 | P00519 | 3/20 | 0.75 |
| ▸ | LCK | P06239 | 3/20 | 0.75 |
| ▸ | MET | P08581 | 3/20 | 0.75 |
| ▸ | PHKG2 | P15735 | 3/20 | 0.75 |
| ▸ | BLK | P51451 | 3/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.75 |
| ▸ | EPHA6 | Q9UF33 | 3/20 | 0.75 |
| ▸ | CIT | O14578 | 2/20 | 0.75 |
| ▸ | STK10 | O94804 | 2/20 | 0.75 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | HCK | P08631 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | AXL | P30530 | 2/20 | 0.75 |
| ▸ | FLT3 | P36888 | 2/20 | 0.75 |
| ▸ | TXK | P42681 | 2/20 | 0.75 |
| ▸ | FRK | P42685 | 2/20 | 0.75 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14854648 | 1.00 | EGFR (0.78) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL14854644 | 1.00 | EGFR (0.78) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL14854646 | 1.00 | EGFR (0.78) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL14854816 | 0.94 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL14854817 | 0.94 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL14854813 | 0.94 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL14854815 | 0.94 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL14854793 | 0.93 | EGFR (0.68) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL15222034 | 0.93 | EGFR (0.69) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL21569003 | 0.93 | EGFR (0.68) | EGFRERBB2GAKABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | claimed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | claimed |
| EP-3222620-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-09-27 | — | — | EP | claimed |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | US | claimed |
| US-9676724-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | claimed |
| EP-2581372-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-06-07 | — | — | EP | claimed |
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2016-06-30 | — | — | US | claimed |
| US-9187458-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-11-17 | — | — | US | claimed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | claimed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | claimed |
| EP-3699177-A1 | PREPARATION METHOD FOR TYROSINE KINASE INHIBITOR AND INTERMEDIATE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200239443-A1 | Preparation Method for Tyrosine Kinase Inhibitor and Intermediate Thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| EP-3222620-B1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | disclosed |
| EP-2581372-A1 | CYANOQUINOLINE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011153942-A1 | CYANOQUINOLINE DERIVATIVES | 天津和美生物技术有限公司 (CN) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246443-B2 | Cyanoquinoline derivatives | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885 |
| US-20200239443-A1 | Preparation Method for Tyrosine Kinase Inhibitor and Intermediate Thereof | ABL1, ABL2, LYN | EGFR 179/4885ERBB2 11/4885GAK 213/4885 |
| US-20130225579-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885 |
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885 |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885GAK 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.